The Impact of TACE Combined Growth Hormone on Immune Function and Prognosis of Patients with Hepatocellular Carcinoma

Objective To evaluate the hepatic arterial chemoembolization(TACE) combined growth hormone on immune and prognosis function in hepatocellular carcinoma patients.Methods All 50 cases primary liver cancer were randomly divided into study group(TACE + growth hormone treatment) and control group(TACE treatment) of 25 cases.Results The study group of 25 patients of response rate(36.0%) was higher than control group(16.7%),after treatment,IgG,IgM of the study group was significantly higher than those before treatment,CD4+ also significantly was higher than that before treatment,while CD8+ was reduced more significantly,CD4+/CD8+ratio was significantly higher than that before treatment,the difference was statistically significant(P0.05).The control group at different times after treatment,the immunological parameters had not change significantly,the difference was not significant.After follow-up one or two years,study group survival rate was higher than the control group(P0.05).Conclusion TACE combined growth hormone is effective in patients with liver cancer,and it can significantly and improve the patient's immune function,and improve the survival rate of liver cancer patients,should be promoted and applied.